AstraZeneca Pharma India Ltd. has received approval to import and market Durvalumab (Imfinzi) for an additional indication in treating unresectable hepatocellular carcinoma, with prior notice given on February 28, 2025.
AI Assistant
Astrazeneca Pharma India Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.